Compare Dow Inc (DOW) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs Inovio Pharmaceuticals Inc — how do they compare? Dow Inc trades at $28.46 (market cap $20.65B), while Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M). The key difference: Dow Inc is far larger — about 184.1× Inovio Pharmaceuticals Inc's market cap, and Dow Inc pays a 4.9% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Inc for 82 Days and Inovio Pharmaceuticals Inc for 43 Days on average.
| DOW | INO | |
|---|---|---|
Market Cap | $20.65B | $112.19M |
Volume | 14,126,943 | 3,201,278 |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $2.65 |
52-Week Low | $20.65 | $0.66 |
Typical Hold Time | 82 Days | 43 Days |
Enterprise Value | $36.34B | $83.51M |
Dividend Yield | 4.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $28.42, up 2.34% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported negative net income of -$2.62B in 2025, though it has beaten EPS estimates in recent quarters. Revenue declined to $39.97B in 2025 from $56.9B in 2022, while cash flow from operations dropped significantly. Analyst consensus is a 'Hold' with a $34.22 price target, indicating potential upside from current levels.
The outlook for DOW is cautious due to profitability challenges and declining revenue, offset by positive earnings surprises and a dividend payment. Key risks include margin pressures and high debt levels, while opportunities lie in cost management and market recovery. Investors should weigh the stock's valuation against its financial health and sector headwinds.
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
